|
|
 |
|
|
|
|
|
|
Department
|
Stem Cell Program
|
|
Hospital Title
|
Associate in Medicine
|
|
Academic Title
|
Associate Professor
|
|
Phone
|
617-919-2013
|
|
Fax
|
617-730-0222
|
|
Email
|
George Daley
|
|
Location
|
300 Longwood Avenue
Karp-7
Boston MA 02115
|
 |
 |
|
|
|
|
|
|
|
George Daley's work focuses on embryonic stem (ES) cells, which have the potential to differentiate into all other cell types. More specifically, his lab is investigating:
|
- The differentiation of hematopoietic (blood producing) stem cells from embryonic cells. Daley and colleagues study hematopoietic development in mouse embryos and in human and mouse ES cells in order to define the molecular genetic programs that enable formation of HSCs in experimental and therapeutic models.
- Self-renewal and differentiation of human ES cells. The lab is using expression cloning together with genomic and proteomic strategies to identify factors that specify human ES cell self-renewal and differentiation. They are building tools for gene expression and gene knock-down in human ES cells to facilitate experimental and therapeutic studies.
- Germ cell development. Daley and colleagues have devised methods for directed differentiation of ES cells into primordial germ cells. and techniques for isolating and transplantating of spermatagonial stem cells from testes. Using this integrated system, they have grown ES-derived germ cell populations into functional sperm.
- Target-directed chemotherapy for chronic myelogenous leukemia (CML): Daley's team has determined how Gleevec works and how cancer cells develop resistance to the drug. His current studies -- now in clinical trials -- are aimed at defining optimal combination chemotherapy regimens to avert resistance.
|
|
|
|
|
|
Dr. Daley received a PhD in biology from MIT and an MD degree from Harvard Medical School through the Harvard-MIT Division of Health Sciences and Technology.
He has been elected to the American Society for Clinical Investigation, and has received research awards from Harvard Medical School, the National Institutes of Health, the New England Cancer Society, the Burroughs Wellcome Fund, the Edward Mallinckrodt, Jr. Foundation, and the Leukemia and Lymphoma Society of America.
|
|
|
|
|
- Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ. Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature 2004; 427: 148-154.
- Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR/ABL. Cell 2003; 112: 831-843.
- Kyba M. Perlingeiro RC. Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109: 29-37.
- Park I-H, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell 2008 online August 7 PMID: 18691744.
- Viswanathan S, *Daley GQ, *Gregory RI. Selective blockade of microRNA processing by Lin-28. Science 2008 320(5872):97-100 [Epub February 21].
- Park I-H, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, and Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008 451(7175):141-6. Epub 2007 Dec 23.
- Azam M, Seeliger MA, Gray N, Kuriyan J, Daley GQ. Kinase activation by mutation of the gatekeeper threonine. Nature Structural and Molecular Biology 2008 online September 14 PMID: doi:10.1038/nsmb.1486.
- Kim K, Lerou P, Yabuuchi A, Lengerke C, Ng K, West J, Kirby A, Daly M, Daley GQ. Histocompatible parthenogenetic murine embryonic stem cells. Science 2007 315(5811):482-6. Epub 2006 Dec 14.
|
|
|
|
|
|
|
